Molecular-targeted agents combination therapy for cancer: developments and potentials (Q38104670)

28 August 2017

Molecular-targeted agents combination therapy for cancer: developments and potentials (English)

1 reference

28 August 2017

Feifei Li

1

1 reference

28 August 2017

Changqi Zhao

series ordinal

2

1 reference

28 August 2017

Lili Wang

series ordinal

3

1 reference

28 August 2017

language of work or name

English

0 references

publication date

12 June 2013

1 reference

International Journal of Cancer

28 August 2017

1 reference

28 August 2017

134

1 reference

28 August 2017

6

1 reference

28 August 2017

1257-1269

1 reference

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

28 August 2017

1 reference

Rational targeting of Notch signaling in cancer

21 January 2018

1 reference

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

21 January 2018

1 reference

Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

21 January 2018

1 reference

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil

21 January 2018

1 reference

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer

21 January 2018

1 reference

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.

21 January 2018

1 reference

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma

21 January 2018

1 reference

Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus be

21 January 2018

1 reference

Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer

21 January 2018

1 reference

Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial

21 January 2018

1 reference

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

21 January 2018

1 reference

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

21 January 2018

1 reference

Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.

21 January 2018

1 reference

A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung cancer

21 January 2018

1 reference

Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: A phase II GINECO trial

21 January 2018

1 reference

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer.

21 January 2018

1 reference

Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group

21 January 2018

1 reference

Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer.

21 January 2018

1 reference

A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies

21 January 2018

1 reference

A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer.

21 January 2018

1 reference

Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxel

21 January 2018

1 reference

Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine.

21 January 2018

1 reference

Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer.

21 January 2018

1 reference

Phase I trial of capecitabine plus everolimus (RAD001) in patients with previously treated metastatic gastric cancer

21 January 2018

1 reference

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

21 January 2018

1 reference

Phase I pharmacokinetic and pharmacodynamic study of the oral protein kinase C beta-inhibitor enzastaurin in combination with gemcitabine and cisplatin in patients with advanced cancer

21 January 2018

1 reference

Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer.

21 January 2018

1 reference

A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer

21 January 2018

1 reference

Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide

21 January 2018

1 reference

Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents

21 January 2018

1 reference

Bevacizumab/docetaxel association is more efficient than docetaxel alone in reducing breast and prostate cancer cell growth: a new paradigm for understanding the therapeutic effect of combined treatment

21 January 2018

1 reference

Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1

21 January 2018

1 reference

Cotargeting MAPK and PI3K signaling with concurrent radiotherapy as a strategy for the treatment of pancreatic cancer

21 January 2018

1 reference

The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel

21 January 2018

1 reference

Inhibition of the PI3K pathway sensitizes fludarabine-induced apoptosis in human leukemic cells through an inactivation of MAPK-dependent pathway

21 January 2018

1 reference

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

21 January 2018

1 reference

Bevacizumab and everolimus in the treatment of patients with metastatic melanoma: a phase 2 trial of the Sarah Cannon Oncology Research Consortium

21 January 2018

1 reference

A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer

21 January 2018

1 reference

Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy.

21 January 2018

1 reference

Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab

21 January 2018

1 reference

Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer

21 January 2018

1 reference

Response to imatinib plus sirolimus in advanced chordoma.

21 January 2018

1 reference

A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma

21 January 2018

1 reference

Pharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma

21 January 2018

1 reference

A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer

21 January 2018

1 reference

Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study

21 January 2018

1 reference

Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial

21 January 2018

1 reference

A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer

21 January 2018

1 reference

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer

21 January 2018

1 reference

Phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment for HER-2-positive locally recurrent or metastatic breast cancer

21 January 2018

1 reference

Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma.

21 January 2018

1 reference

Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours

21 January 2018

1 reference

A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma.

21 January 2018

1 reference

Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance

21 January 2018

1 reference

Sorafenib and Mek inhibition is synergistic in medullary thyroid carcinoma in vitro.

21 January 2018

1 reference

Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis

21 January 2018

1 reference

MEK and EGFR inhibition demonstrate synergistic activity in EGFR-dependent NSCLC.

21 January 2018

1 reference

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

21 January 2018

1 reference

Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy.

21 January 2018

1 reference

Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas

21 January 2018

1 reference

Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer

21 January 2018

1 reference

Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations

21 January 2018

1 reference

AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity

21 January 2018

1 reference

Negative feedback and adaptive resistance to the targeted therapy of cancer

21 January 2018

1 reference

Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.

21 January 2018

1 reference

A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma

21 January 2018

1 reference

The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.

21 January 2018

1 reference

Epidermal growth factor receptor regulates aberrant expression of insulin-like growth factor-binding protein 3

21 January 2018

1 reference

Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib

21 January 2018

1 reference

Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.

21 January 2018

1 reference

Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer

21 January 2018

1 reference

The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib

21 January 2018

1 reference

Synergy between an IGF-1R antibody and Raf/MEK/ERK and PI3K/Akt/mTOR pathway inhibitors in suppressing IGF-1R-mediated growth in hematopoietic cells.

21 January 2018

1 reference

Crosstalk between the PI3K/mTOR and MEK/ERK pathways involved in the maintenance of self-renewal and tumorigenicity of glioblastoma stem-like cells.

21 January 2018

1 reference

Targeting V600EB-Raf and Akt3 using nanoliposomal-small interfering RNA inhibits cutaneous melanocytic lesion development.

21 January 2018

1 reference

Response and determinants of cancer cell susceptibility to PI3K inhibitors: combined targeting of PI3K and Mek1 as an effective anticancer strategy

21 January 2018

1 reference

PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation

21 January 2018

1 reference

In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.

21 January 2018

1 reference

Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells

21 January 2018

1 reference

Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo

21 January 2018

1 reference

The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.

21 January 2018

1 reference

Compensatory pathways induced by MEK inhibition are effective drug targets for combination therapy against castration-resistant prostate cancer

21 January 2018

1 reference

Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models

21 January 2018

1 reference

JAK2/STAT5 inhibition circumvents resistance to PI3K/mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancer

21 January 2018

1 reference

A phase I study of bortezomib in combination with standard 5-fluorouracil and external-beam radiation therapy for the treatment of locally advanced or metastatic rectal cancer

21 January 2018

1 reference

A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer

21 January 2018

1 reference

A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias

21 January 2018

1 reference

A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors.

21 January 2018

1 reference

Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia

21 January 2018

1 reference

Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors

21 January 2018

1 reference

A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma

21 January 2018

1 reference

Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study

21 January 2018

1 reference

HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab.

21 January 2018

1 reference

Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycin

21 January 2018

1 reference

First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: a phase I/II open-label and double-blind study.

21 January 2018

1 reference

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study

21 January 2018

1 reference

A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab

21 January 2018

1 reference

Randomized phase II trial of carboplatin and paclitaxel with or without lonafarnib in first-line treatment of epithelial ovarian cancer stage IIB-IV.

21 January 2018

1 reference

Phase II trial of the farnesyltransferase inhibitor tipifarnib plus fulvestrant in hormone receptor-positive metastatic breast cancer: New York Cancer Consortium Trial P6205.

21 January 2018

1 reference

A phase I clinical trial of safingol in combination with cisplatin in advanced solid tumors

21 January 2018

1 reference

Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer

21 January 2018

1 reference

Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years

21 January 2018

1 reference

Cyclooxygenase-2 inhibition does not improve the reduction in ductal carcinoma in situ proliferation with aromatase inhibitor therapy: results of the ERISAC randomized placebo-controlled trial

21 January 2018

1 reference

Combination anastrozole and fulvestrant in metastatic breast cancer

21 January 2018

1 reference

Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia

21 January 2018

1 reference

Single-arm phase II study of conformal radiation therapy and temozolomide plus fractionated stereotactic conformal boost in high-grade gliomas: final report.

21 January 2018

1 reference

Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis o

21 January 2018

1 reference

Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

21 January 2018

1 reference

Hsp90 molecular chaperone inhibitors: are we there yet?

21 January 2018

1 reference

Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins

21 January 2018

1 reference

Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT.

21 January 2018

1 reference

Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models

21 January 2018

1 reference

Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy

21 January 2018

1 reference

Optimized combination therapy using bortezomib, TRAIL and TLR agonists in established breast tumors.

21 January 2018

1 reference

A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model.

21 January 2018

1 reference

Wnt/beta-catenin signaling in cancer stemness and malignant behavior

21 January 2018

1 reference

Wnt signaling in stem and cancer stem cells

21 January 2018

1 reference

Targeting Notch to target cancer stem cells.

21 January 2018

1 reference

Wnt activity defines colon cancer stem cells and is regulated by the microenvironment

21 January 2018

1 reference

Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia

21 January 2018

1 reference

The crosstalk of mTOR/S6K1 and Hedgehog pathways

21 January 2018

1 reference

XIAP antisense oligonucleotide (AEG35156) achieves target knockdown and induces apoptosis preferentially in CD34+38- cells in a phase 1/2 study of patients with relapsed/refractory AML.

21 January 2018

1 reference

Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia

21 January 2018

1 reference

Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial

21 January 2018

1 reference

Combining targeted therapy with immunotherapy (interferon-α): Rational, efficacy in gastrointestinal stromal tumor model and implications in other malignancies.

21 January 2018

1 reference

Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay

21 January 2018

1 reference

A Phase Ib, Dose-Finding Study of Erlotinib in Combination With a Fixed Dose of Pertuzumab in Patients With Advanced Non–Small-Cell Lung Cancer

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IJC.28261

1 reference

28 August 2017

1 reference